Lv43
790 积分 2024-05-13 加入
Optimizing Early Clinical Investigations in Cancer Immunotherapy: The Translational Journey of RG6292, a Novel, Selective Treg‐Depleting Antibody
5小时前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
4天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
4天前
已完结
Adaptive phase I–II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies
4天前
已完结
Design Strategy and Consideration for Oncology Dose-Optimization: An Industry Perspective
4天前
已完结
Dose Optimization for Novel Oncology Agents: Design Options and Strategies
4天前
已完结
BCMA-CAR T-cells in a patient with relapsing idiopathic inflammatory myositis after CD19-CAR T-cells
5天前
已完结
Include rare, treatable IL-1-mediated autoinflammatory diseases in differential diagnosis of chronic or periodic inflammation
12天前
已完结
DB-2304, a Duality Immune Modulating Antibody‒Drug Conjugate (DIMAC) targeting BDCA2, displays strong potency in the suppression of pDC functions
17天前
已关闭
Advances And Challenges in Immunosuppressive Antibody Drug Conjugates
25天前
已完结
皖公网安备34019202002308
